Search

Chromic citrate

Bevacizumab

[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA

Viltolarsen

[A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval

Satralizumab

[A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after

Betula pendula tar oil

[L1113] By the FDA, it is considered under the substances approved to be added to the food.

Technetium Tc-99m oxidronate

[L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.

Omega-3-carboxylic acids

[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]

Alemtuzumab

[L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

Belatacept

FDA approved on June 15, 2011.

Prademagene zamikeracel

[L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering